BioNTech SE ADR

Is $PFE (+1,1 %) a turnaround candidate?

After the hype surrounding the corona vaccines, Pfizer is in crisis: the share price has collapsed, sales are weakening and new blockbusters are a long time coming. But what is the real situation? Is there any hope of a turnaround - or will the shares remain a construction site?

A look at the current situation

Pfizer is in a difficult situation. After peaking during the pandemic, the share price has stabilized at around 25 euros, a far cry

far from the peak values of over 40 euros. Sales in the third quarter of 2024 amounted to USD 17.7 billion - an increase of 31% compared to the previous year. However, excluding the COVID-19 products Paxlovid and Comirnaty, growth remains moderate at 14%. Pfizer is struggling to stabilize its sales in other areas, while older drugs such as Ibrance (-13%) or Xeljanz (-36%) are increasingly losing market share.

The dividend yield of around 6.5 % appears attractive at first glance, but is it sustainable? Pfizer paid out USD 7.1 billion in dividends in the first nine months of the year, while spending on research and development amounted to USD 7.8 billion. The dividend is currently still covered, but is heavily dependent on future growth impetus.

Where is the money currently coming from?

Pfizer continues to generate a large part of its revenue from products that played a key role during the pandemic. The most important sources of revenue in the third quarter of 2024 were

• 1. Paxlovid2.7 billion USD (+ 2.5 billion USD compared to the previous year).
• 2. Comirnaty (COVID-19 vaccine)1.4 billion USD (+9 %).
• 3. Eliquis (anticoagulant): USD 1.6 billion (+9 %).
• 4. Prevnar (pneumococcal vaccine): USD 1.8 billion.
• 5. Vyndaqel (treatment of transthyretin amyloidosis): USD 1.4 billion (+63 %).
• 6. Ibrance (breast cancer treatment): USD 1.1 billion (-13 %).
• 7. Xtandi (prostate cancer): USD 561 million (+28 %).
• 8. Padcev (new cancer therapy): USD 409 million.
• 9. Nurtec ODT/Vydura (migraine): USD 337 million (+45%).
• 10. Abrysvo (RSV vaccine): USD 356 million.

Comparing these figures with the previous year, it is clear that COVID-19 products continue to play a significant role, while other areas need to grow more strongly to fill the gap.

The pipeline: Hope in 108 acts?

With 108 projects in the pipeline, Pfizer has a promising basis, at least on paper. This is broken down as follows:

• Phase 1: 46 projects.
• Phase 2: 28 projects.
• Phase 3: 30 projects.
• Phase 4 (registration): 4 projects.

Products in registration

ADCETRIS (brentuximab vedotin): A therapy for diffuse large B-cell lymphoma (DLBCL). The global market for DLBCL therapies is estimated to be worth around USD 5 billion by 2027.

COVID-19 vaccine (in collaboration with $BNTX (+4,77 %)
): Extension of approval for children aged 5 to 11 years in the USA. The market for COVID-19 vaccines remains significant, particularly with a focus on younger age groups.

COVID-19 vaccine (in collaboration with
$BNTX (+4,77 %)
): Extension of approval for children aged 6 months to 4 years in the USA. Vaccination of this age group is crucial to contain the pandemic.

NGENLA (Somatrogon): Treatment for growth hormone deficiency in adults (in the EU as an orphan drug classified). The market for growth hormone therapies is estimated to be worth around USD 4 billion by 2025.

Although these products offer significant sales potential, it is unlikely that they alone will be sufficient for a complete turnaround of Pfizer. A sustained recovery requires a continuous pipeline of innovative products, successful launches and effective market strategies. However, the products and acquisitions can make an important contribution to the stabilization and future growth of the company.

Blockbuster of the future?

Progress in the areas of oncology, vaccines and innovative drugs such as weight loss products are particularly important. Pfizer is investing heavily in research and development, with a budget of USD 11 to 12 billion for 2024. Some of the most promising projects are

Danugliprone (Phase 2): A GLP-1 agonist for weight loss. But Pfizer is struggling with problems here: The original twice-daily formulation was discontinued due to severe side effects - nausea and vomiting - nausea and vomiting. The sufferer may think with a twinkle in his eye, 'actually works great'. But there must be gentler ways to lose weight. Pfizer is now concentrating on a once-daily dose. Results have not yet been communicated, but should come in 2024. The market for weight loss drugs is huge and could grow to over USD 50 billion by 2030, but the competition is fierce. $NOVO B (-2,35 %) (Wegovy, Ozempic) $LLY (+0,29 %) (Orforglipron) are already leading the way here.

mRNA combivaccines (COVID-19 and influenza - phase 3)This vaccine is in phase 3 and, if successfully approved, could become a sales driver as the market for combined vaccines is estimated at over USD 10 billion.

Oncology therapies (phase 3): Pfizer is working on several cancer therapies, including Talzenna (prostate cancer) and Braftovi/Mektovi (lung cancer). Both are in phase 3 and could generate initial sales from 2025.

Abrysvo (RSV vaccine - Approved)This vaccine is already approved and addresses a market that is expected to grow to over 8 billion USD by 2027.

The challenges: Competition and problems

Despite its promising pipeline, Pfizer faces a number of obstacles. Especially in the area of weight loss drugs, the competition from Novo Nordisk and Eli Lilly is immense. With Semaglutide (Ozempic/Wegovy) and Orforglipron, both companies already have established products or candidates that have performed excellently in clinical trials. Pfizer must make rapid progress here to avoid falling further behind.

Another problem is the dependence on COVID-19 products. While Paxlovid and Comirnaty continue to generate sales in the short term, demand is declining sharply as the pandemic increasingly fades into the background. Without new blockbusters, it will be difficult to compensate for these revenues.

Conclusion: Is Pfizer a turnaround candidate?

The answer is: Yes, but with conditions. With innovative products such as Danuglipron and new cancer therapies, the pipeline certainly offers potential, but Pfizer is under immense pressure. The competition is strong and time is running out - especially in the field of weight loss drugs. The dividend is also only secure in the long term if new products are successfully launched on the market.

Pfizer has the resources to achieve a turnaround, but investors need patience. If the company achieves initial success with its new drugs in 2025 or 2026, the share price could recover. Until then, however, it remains a shaky candidate - with a lot of risk, but also a lot of potential.

If you've made it this far, I look forward to seeing you on the website or on Instagram. Thank you :)

Continue on my website

https://www.dividenden-rechner.de/

https://www.instagram.com/p/DCeo-cCiHPW/?img_index=1

Analsyst updates, 08.11.

⬆️⬆️⬆️

- GOLDMAN upgrades BIONTECH from Neutral to Buy and raises price target from USD 90 to USD 137. $BNTX (+4,77 %)

- BOFA raises target price for UNDER ARMOUR from USD 9 to USD 13. Neutral. $UAA (+1,55 %)

- DEUTSCHE BANK RESEARCH raises the price target for DELIVERY HERO from EUR 29 to EUR 35. Hold. $DHE

- DEUTSCHE BANK RESEARCH raises the price target for SIEMENS from EUR 197 to EUR 200. Buy. $SIE (-0,49 %)

- JEFFERIES raises the price target for HOCHTIEF from EUR 135 to EUR 138. Buy. $HOT (+1,18 %)

- DEUTSCHE BANK RESEARCH raises the price target for SIEMENS HEALTHINEERS from EUR 60 to EUR 62. Buy. $SHL (-1,39 %)

- DEUTSCHE BANK RESEARCH raises the price target for NORDEX from EUR 18 to EUR 19. Buy. $NDX1 (-3,13 %)

- DEUTSCHE BANK RESEARCH raises the price target for RATIONAL from 832 EUR to 841 EUR. Hold. $RAA (+1,82 %)

- DEUTSCHE BANK RESEARCH raises the target price for AXA from 37 EUR to 39 EUR. Buy. $CS (+0,12 %)

- WARBURG RESEARCH raises the price target for BASTEI LÜBBE from EUR 11.70 to EUR 12.20. Buy. $BST (+0 %)

- DEUTSCHE BANK RESEARCH raises the price target for ARCELORMITTAL from EUR 28 to EUR 29. Buy. $MT (+1,36 %)

- DZ BANK raises the price target for SWISS RE from CHF 130 to CHF 140. Buy. $SREN (+1,35 %)

- ODDO BHF raises the price target for HEIDELBERG MATERIALS from EUR 99 to EUR 110. Neutral. $HEI (-0,13 %)

- KEPLER CHEUVREUX raises the price target for DAIMLER TRUCK from EUR 35 to EUR 41. Hold. $DTG (-0,1 %)

- KEPLER CHEUVREUX upgrades REDCARE PHARMACY from Reduce to Hold. $RDC (-3,11 %)

- ODDO BHF raises the price target for HENKEL from EUR 67 to EUR 73. Neutral. $HEN (+0,21 %)

- ODDO BHF raises the price target for FREENET from EUR 27 to EUR 28. Neutral. $FNTN (-0,1 %)

- BARCLAYS raises the target price for ABOUT YOU from EUR 3.10 to EUR 3.40. Underweight. $YOU (+1,64 %)

- BARCLAYS raises the target price for NEMETSCHEK from EUR 108 to EUR 125. Overweight. $NEM (-1,12 %)

⬇️⬇️⬇️

- BOFA lowers the price target for PINTEREST from USD 45 to USD 39. Buy. $PINS

- WARBURG RESEARCH lowers the price target for DAIMLER TRUCK from EUR 56 to EUR 55. Buy. $DTG (-0,1 %)

- UBS lowers the price target for JCDECAUX from EUR 21.60 to EUR 18.50. Neutral. $DEC (-1,01 %)

- WARBURG RESEARCH lowers the price target for ADTRAN HOLDING from EUR 9.70 to EUR 9.30. Buy. $ADTN (+5,64 %)

- ODDO BHF lowers the price target for NORDEX from EUR 18 to EUR 17. Outperform. $NDX1 (-3,13 %)

- BARCLAYS lowers the target price for VESTAS from DKK 99 to DKK 80. Underweight. $VWS (-1,58 %)

- KEPLER CHEUVREUX lowers the price target for FRAPORT from EUR 62 to EUR 59. Buy. $FRA (-1,29 %)

- BARCLAYS lowers the target price for GSK from GBP 15.50 to GBP 14.50. Equal-Weight. $GSK

- BERENBERG lowers the price target for COMPUGROUP from EUR 23 to EUR 21. Buy. $COP (-0,21 %)

- BERENBERG lowers the price target for JUNGHEINRICH from EUR 41 to EUR 39. Buy. $JUN3 (+1,77 %)

- JEFFERIES lowers the target price for SUSS MICROTEC from EUR 87 to EUR 75. Buy. $SMHN (+3,96 %)

08.11.2024

US Federal Reserve lowers key interest rate by 25 basis points
+ Goldman raises Biontech to 'Buy' - target up to 137 dollars + Bechtle higher - remains optimistic for the final quarter + Redcare at three-year high

The US Federal Reserve has lowered its key interest rate by 25 basis points. This decision had been firmly expected on the markets. The decision was taken unanimously by the Federal Open Market Committee (FOMC). The decision, which was taken in the week of Donald Trump's re-election as US president, followed an initial cut of 50 basis points in September and will bring the key interest rate to a range of 4.50 to 4.75 percent. US Federal Reserve officials have said that these rate cuts are justified because they are more confident that inflation will return to the central bank's target and because they believe that interest rates are still high enough to dampen economic activity even after the recent cuts. "The Council judges that the risks to achieving the employment and inflation objectives are roughly balanced," the Fed's statement said. Trump's election victory has the potential to reshape the economic outlook as the Republicans' likely majority in Congress allows for a sweeping change of course on taxes, spending, immigration and trade. The changing outlook has in turn raised questions on Wall Street as to whether the Fed will change its previous expectation that interest rates could be steadily lowered over the next year or two.

The US investment bank Goldman Sachs has Biontech $BNTX (+4,77 %) from "Neutral" to "Buy" and raised its price target from 90 to 137 US dollars. Analyst Chris Shibutani now includes BNT327 - an antibody that the Mainz-based company is testing against various solid tumors - in his buy recommendation published on Friday. The investment story is moving further away from the difficult-to-assess Covid vaccine market.

With Bechtle $BC8 (-0,68 %) a very weak 2024 share was in demand in pre-market trading on Friday. Following the IT service provider's final quarterly figures, the shares rose by 2.7 percent in Tradegate trading compared to the Xetra closing price. An attempt to recover from the low since 2020 thus continues. So far this year, the share has lost around 28% despite the recent stabilization and a gain of 3.3% the day before. Since the record high in 2021, the share price has even more than halved. According to a trader, the business environment for Bechtle in the third quarter was characterized by challenges. The results showed a mixed picture with weak demand in the core markets of Germany and France, but solid organic growth in other international markets, and another trader emphasized that Bechtle is optimistic about the future and continues to expect an improvement in the fourth quarter. However, the first mentioned trader sees risks in the fact that public IT spending in Germany could suffer for the time being from the end of the traffic light coalition.

The good performance of the shares of Redcare Pharmacy $RDC (-3,11 %) continued on Friday with a high since December 2021. The shares were already the biggest MDax gainer in 2023 and are among the better performers in the mid-cap index this year. On Friday, they rose by up to three percent to EUR 157.60 in early Xetra trading. So far this year, they have repeatedly struggled in the EUR 153 to 154 range.

Friday: Stock market dates, economic data, quarterly figures

ex-dividend of individual stocks

Apple USD 0.25

Pfizer USD 0.42

ConocoPhillips USD 0.78

Wells Fargo USD 0.4

Quarterly figures / company dates USA / Asia

07:00 Sony quarterly figures

Untimed: Baxter International quarterly figures

Quarterly figures / Company dates Europe

07:00 LEG Immobilien | Richemont Quarterly figures

07:30 Bechtle | Deutsche Wohnen Quarterly figures

08:00 Banca Monte dei Paschi | International Consolidated Airlines Quarterly figures

10:00 Freenet earnings call and strategy update until 2028

10:30 Bechtle analyst and press conference

14:00 Pernod Ricard AGM

Economic data

• 06:00 JP: Leading indicators 9/24 (preliminary)
• 08:00 DE: Domestic tourism | Truck toll mileage index October
• 09:00 DE: Bundestag, Plenum, Berlin
• 11:30 DE: Government Pk, Berlin
• 16:00 US: Consumer Sentiment Index Uni Michigan (1st survey) November FORECAST: 71.0 previous: 70.5

Analyst updates, 05.11.

⬆️⬆️⬆️

- ODDO BHF raises the price target for BIONTECH from USD 110 to USD 130. Outperform. $BNTX (+4,77 %)

- BARCLAYS raises the price target for AIRBUS from EUR 161 to EUR 165. Overweight. $AIR (+0,86 %)

- CITIGROUP raises the price target for SCOUT24 from EUR 91 to EUR 94.50. Buy. $G24 (-0,06 %)

- WARBURG RESEARCH raises the price target for REDCARE PHARMACY from EUR 174 to EUR 176. Buy. $RDC (-3,11 %)

- DEUTSCHE BANK RESEARCH raises the price target for RYANAIR from EUR 17 to EUR 17.50. Hold. $RYA (-0,66 %)

- BERNSTEIN rates EBAY from Market-Perform to Outperform. Target price USD 70. $EBAY (+2,34 %)

- ODDO BHF raises the price target for SALZGITTER from EUR 14 to EUR 15.50. Underperform. $SZG (-2,22 %)

- BARCLAYS raises the target price for COMMERZBANK from EUR 16 to EUR 17. Equal-Weight. $CBK (-0,97 %)

- BARCLAYS raises the target price for MTU from EUR 295 to EUR 340. Equal-Weight. $MTX (+1,77 %)

- MORGAN STANLEY rates LUFTHANSA to Equal-Weight. Target price EUR 7. $LHA (-1,5 %)

- BERENBERG raises the price target for DEUTSCHE KONSUM REIT from EUR 3.50 to EUR 5. Hold.

⬇️⬇️⬇️

- GOLDMAN lowers the price target for MERCEDES-BENZ from EUR 65 to EUR 63. Buy. $MBG (-0,53 %)

- UBS lowers target price for 1&1 from EUR 21.60 to EUR 21. Buy.

- WARBURG RESEARCH lowers the price target for GFT TECHNOLOGIES from EUR 40 to EUR 37.50. Buy. $GFT (-0,68 %)

- HAUCK AUFHÄUSER IB lowers the price target for ECKERT & ZIEGLER from EUR 63.50 to EUR 55. Buy. $EUZ (-1,5 %)

- BARCLAYS lowers the price target for BNP PARIBAS from EUR 90 to EUR 85. Overweight. $BNP (-0,36 %)

- BERENBERG downgrades SCHNEIDER ELECTRIC from Buy to Hold and lowers price target from EUR 261 to EUR 255. $SU (+0,85 %)

- BERENBERG lowers the price target for BEFESA from EUR 41 to EUR 31. Buy. $BFSA (-2,44 %)

05.11.2024

US elections underway + Nvidia benefits from Dow admission and processor news + PALANTIR accelerates growth thanks to AI + DHL earns less on the bottom line + Biontech increases revenue and profit

The first decisions of the US presidential election have been made: In the small town of Dixville Notch in the state of New Hampshire, Democrat Kamala Harris and her Republican opponent Donald Trump tied by 3 votes to 3, as announced on a hand-written board shortly after midnight (local time). The voter turnout was 100 percent. The polling station in Dixville Notch has been opening at midnight on election day since 1960.

The index provider S&P Dow Jones Indices announced on Friday after the close of trading that Nvidia $NVDA (+1,83 %) will be included in the US Dow Jones Industrial index this Friday. For the manufacturer of chips related to artificial intelligence (AI), the shares of semiconductor company Inte l$INTC (+3,55 %) have to make way. Nvidia's market capitalization has increased tenfold over the past two years to around 3.3 trillion dollars, while Intel's has fallen by just under a fifth to 100 billion dollars. Various media outlets are also reporting that Nvidia is developing its own ARM processors for notebooks, which could be launched on the market in September 2025. Until now, the company was primarily known for its graphics processors in the consumer segment. ARM processors are primarily used in mobile devices such as smartphones and tablets.

Palantir $PLTR (+0,98 %) Technologies presented exceptionally strong business figures in the third quarter of 2024. The company reported year-on-year growth of 30%, bringing total revenue to USD 726 million.

This dynamic development is particularly attributable to rapid growth in the United States, where sales climbed by 44% to USD 499 million. The US commercial business in particular increased its sales by an impressive 54% to USD 179 million. The area of government contracts also contributed significantly to the success, recording an increase of 40% to USD 320 million. This dynamic development is due in particular to the rapid growth in the United States, where sales climbed by 44% to USD 499 million. The US commercial business in particular increased its sales by an impressive 54% to USD 179 million. The area of government contracts also contributed significantly to the success and recorded an increase of 40% to USD 320 million. This exceeded analysts' expectations.

The logistics group DHL $DHL (-0,9 %) earned less on the bottom line in the third quarter due to increased personnel costs, a lower number of letters sent and weak margins for air transportation, among other things. Net profit fell by almost seven percent to EUR 751 million, the Group announced on Tuesday when presenting detailed figures for the third quarter in Bonn. As has been known since the end of October, DHL was able to keep earnings before interest and taxes (EBIT) stable at just under 1.4 billion euros - thanks in part to positive special effects. When presenting the key figures, DHL also lowered its forecast for operating profit in the current year and for 2026. However, the medium-term targets for free cash flow and investments were confirmed. Compared to the previous year, revenue increased by six percent to 20.6 billion euros.

Biontech $BNTX (+4,77 %) significantly increased sales in the third quarter thanks to the successful market launch of adapted Covid-19 vaccines for the 2024/2025 vaccination season and also earned more on the bottom line. Nevertheless, the company now sees sales for the year as a whole at the lower end of the forecast range. In view of the cautious outlook, the share price held up slightly.

Tuesday: Stock market dates, economic data, quarterly figures

Quarterly figures / company dates USA / Asia

08:30 Nintendo half-year figures

13:00 Dupont quarterly figures

No time specified: USA: Yum! Brands | Cummins quarterly figures

Quarterly figures / Company dates Europe

06:45 Redcare Pharmacy quarterly figures

07:00 DHL Group | Fraport | Fresenius Medical Care | Krones | Zalando | Norma Group Quarterly figures

07:30 Hugo Boss | Uniper | Bouygues Quarterly figures

08:00 Schaeffler | Vestas Wind | AB Foods quarterly figures

08:30 DHL Group PK

09:00 Audi 9 months results | Zalando | Hugo Boss PK

09:30 Zalando Analyst Conference

10:00 DHL Group Analyst Conference

10:30 Fraport BI-PK

11:00 Hugo Boss | Schaeffler Analyst Conference

14:00 Ferrari quarterly figures

Unscheduled: Unicredit quarterly figures

Economic data

• 08:45 FR: Industrial Production September FORECAST: -0.5% yoy previous: +1.4% yoy
• 10:30 UK: Purchasing Managers' Index/PMI non-manufacturing (2nd release) October OUTLOOK: 51.8 1st release: 51.8 previous: 52.4
• 14:30 US: Trade Balance September FORECAST: -84.00 bn USD previously: -70.43 bn USD
• 16:00 US: ISM Non-Manufacturing Index October FORECAST: 53.7 points PREVIOUS: 54.9 points
• Without time US: Presidential and congressional elections

Biontech Q3 2024 $BNTX (+4,77 %)

Financial performance:

• Revenue: BioNTech's revenue for Q3 2024 amounted to € 1,244.8 million, an increase compared to € 895.3 million in Q3 2023. In the first nine months of 2024, revenue totaled € 1,561.1 million, a decrease compared to € 2,340.0 million in the same period of 2023.
• Net profit: In the third quarter of 2024, the company recorded a net profit of € 198.1 million, an increase compared to € 160.6 million in the previous year. For the first nine months, however, BioNTech recorded a net loss of € 924.8 million, compared to a net profit of € 472.4 million in the previous year.
• Operating result: Operating profit fell to € 10.5 million in the third quarter of 2024 compared to € 73.1 million in the third quarter of 2023.
• Liquidity: Cash, short-term securities and deposits amounted to € 17.8 billion as at September 30, 2024, indicating a strong liquidity position.

Balance sheet analysis:

• Assets and liabilities: Total assets amounted to € 22,401.2 million in September 2024, a slight decrease compared to € 23,006.3 million at the end of 2023. Total liabilities amounted to € 3,286.7 million, of which € 2,522.5 million were current liabilities.
• Equity: Equity totaled € 19,114.5 million and reflects a solid financial structure with low debt due to high equity reserves.

Findings from the income statement:

• Revenue sources: Revenue is predominantly generated from the sale of COVID-19 vaccines, which has increased further due to the approval of vaccine variants.
• Costs and margins: The cost of goods sold increased to € 178.9 million in the third quarter of 2024 (compared to € 161.8 million in the third quarter of 2023). Operating margins were impacted by high R&D expenditure and operating losses.

Cash flow analysis:

• Operating activities: Operating cash flow is positive and supported by strong sales.
• Investment activities: High expenditure due to investments in financial assets and acquisitions.
• Financing activities: Minimal activity, with focus on building liquidity.

Key figures and profitability:

• ROE and ROIC: Net loss over the nine months indicates negative returns, even if not explicitly calculated.
• Debt and interest coverage ratio: Due to high equity reserves and low borrowing costs, there is a low gearing ratio and solid interest coverage.

Segment analysis:

• COVID-19 vaccines: The main source of sales, supported by the introduction of adapted vaccine variants.
• Oncology pipeline: Intensive R&D investments are flowing into ongoing studies and pipeline developments in oncology.

Competitive positioning:

• Market position: BioNTech holds a strong position in the COVID-19 vaccine market and is actively expanding in oncology.
• Industry trends: Demand for COVID-19 vaccines remains strong, accompanied by a growing focus on advances in mRNA technology.

Forecasts and management comments:

• Sales forecast: Annual sales in 2024 are expected to be at the lower end of the forecast range of € 2.5-3.1 bn.
• Strategic goals: The company is focused on expanding its oncology pipeline and consolidating its leading role in mRNA technology.

Risks and opportunities:

• Risks: Heavy dependence on COVID-19 vaccine sales, regulatory challenges and high R&D costs.
• Opportunities: Expansion in the oncology segment and development of new vaccines.

Summary and strategic implications:

• Financial stability: BioNTech demonstrates high financial stability with robust cash reserves and a leading position in the COVID-19 vaccine market.
• Challenges and growth potential: Despite the net loss and high R&D spending, the strategic focus on oncology and mRNA technology shows significant growth potential. However, in order to maintain its competitiveness in a dynamic environment, the company must keep operational risks under control and continue to promote innovation.

In summary, BioNTech shows a solid basis for growth through its mRNA expertise and pipeline in oncology. However, the company needs to overcome its dependence on COVID-19 sales and ensure operational profitability to maintain financial stability and investor confidence in the long term.

Five positive aspects of BioNTech's current performance:

Revenue growth in Q3 2024: BioNTech reported significant revenue growth in Q3 2024, reaching €1,244.8 million, compared to €895.3 million in Q3 2023. This increase was primarily due to the successful launch of COVID-19 variant-adapted vaccines.

Strong liquidity position: At the end of Q3 2024, BioNTech had a solid liquidity base of EUR 17.8 billion in the form of cash and investments in securities. This reserve provides financial security to support ongoing research and development and future strategic initiatives.

Progress in oncology pipeline: BioNTech reported significant progress in its oncology pipeline, including the initiation of Phase 2 trials for BNT327/PM8002 in small cell lung cancer and triple negative breast cancer. These developments demonstrate the company's ambition to diversify beyond COVID-19 vaccines.

Positive clinical data for mRNA cancer vaccine: BioNTech announced positive Phase 2 results for its mRNA cancer vaccine candidate BNT111 in cutaneous melanoma, highlighting the potential of its mRNA technology in oncology as well.

Strategic partnerships: BioNTech continues to expand its strategic partnerships with companies such as Pfizer, Genentech and Biotheus. These collaborations strengthen its research capabilities and expand its market presence.

Five negative aspects of BioNTech's current performance:

Net loss for the first nine months: Despite a profitable Q3, BioNTech reported a net loss of €924.8 million for the first nine months, compared to a net profit of €472.4 million last year. This indicates financial challenges.

High R&D costs: Research and development expenses increased significantly to €1,642.4 million for the first nine months of 2024, compared to €1,205.3 million for the same period in 2023. This is weighing on the company's profitability.

Decline in turnover in the first nine months: Sales for the first nine months of 2024 amounted to EUR 1,561.1 million, compared to EUR 2,340.0 million in the previous year, reflecting a decline in overall sales performance.

Negative operating results: Operating profit in Q3 2024 amounted to only EUR 10.5 million, a significant decrease compared to EUR 73.1 million in Q3 2023, highlighting operational inefficiencies.

Dependence on COVID-19 vaccine sales: BioNTech's financial performance is highly dependent on COVID-19 vaccine sales, which poses a risk if demand fluctuates or new competitors enter the market.

Another depot update. Values are not quite correct but the reference value is. The crypto values are completely wrong but I have no idea where the entry price is (made kind of annoying at Coinbase). The best positions at the moment are $SOFI (+6,49 %)
$FTNT (+1,45 %)
$D05 (+0,52 %) . The interesting values for me are $BNTX (+4,77 %)
$FYB (-1,27 %)
$SNOW (+12,89 %)

BioNTech $BNTX (+4,77 %) has just announced its quarterly figures.

The earnings per share (EPS) are $0,89 and exceeds expectations of -$1,67.

The turnover amounted to $1,37 billion and is also above expectations of $639,12 million.

Photo: Andreas Arnold/dpa

Hello everyone,

it's time for some feedback again!

Briefly about the long-term strategy. I currently save monthly $IWDA (+1,14 %)
$EIMI (+0,34 %) and $WSML (+1,57 %) . I definitely want to increase the ETF share over the next few years. I definitely invested too little here at the beginning.

With very small sums I invest in stocks like $ASML (+2,04 %)
$AAPL (+0,98 %)
$MCD (-0,33 %)
$MC (-1,36 %)
$MSFT (-0,01 %)
$AMZN (-2,02 %) and co. There I have split the execution to 2x per month. If it drops significantly, I buy in tranches.

So that the dividend doesn't come up short, I still have stocks like $O (+1,52 %)
$KO (+1,48 %)
$DGE (-0,52 %) and my overweight $BAT . I don't work with savings plans for dividend stocks. Here I only buy in tranches if the share falls significantly. Provided I am still convinced of the investment. I try to focus exclusively on established quality companies.

I only see these candidates here as a trade. I will definitely part with them if the prices are attractive $BNTX (+4,77 %)
$FXPO (-0,8 %)
$ORSTED (-1,37 %)
$PYPL (+1,34 %)
$YSN (+3,18 %)
$SIX2 (-1,16 %) .

Conclusion

-Increase ETF share

-Increase the investment amount of the individual positions

-Reduce overall portfolio positions

I look forward to any constructive criticism!